Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
WALTHAM, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2019.
Minerva has five late-stage clinical efficacy trials ongoing with three product candidates, including a Phase 3 trial with roluperidone (MIN-101) for negative symptoms in patients with schizophrenia, a Phase 2b trial with MIN-117 for major depressive disorder (MDD) associated with anxiety and three Phase 2b trials with seltorexant (MIN-202) for insomnia disorder and MDD.
“I am very pleased to provide an update and insights into the progress we are making in all of our studies,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “We have updated forecast timelines for the roluperidone Phase 3 study and the MIN-117 Phase 2b study, both of which we now expect to read out in the fourth quarter of this year.
“Our three seltorexant studies will now read out sooner than anticipated, with patient enrollment completed in all three,” said Dr. Luthringer. “We expect to report top-line results from both our first MDD trial and our insomnia trial in the second quarter of 2019, and we expect top-line results from our second MDD trial in the third quarter of 2019.
“The new timelines reflect the latest information available from our sites, as well as the care that we are taking both in recruiting subjects who meet stringent entry criteria and in engaging well-trained clinical investigators to evaluate the therapeutic benefit of our product candidates,” said Dr. Luthringer. “I am pleased to report that patient selection to date has met these standards and the investigators are performing well. Our focus continues to be on trial conduct and data quality.”
- The Company is actively enrolling patients in the pivotal Phase 3 trial with roluperidone (clinicaltrials.gov identifier: NCT03397134). Approximately 60 sites in the U.S. and Europe are participating in this trial, and target enrollment is approximately 500 patients. Completion of full enrollment is now expected in the second half of 2019, and top-line results from the 12-week, double-blind portion of the trial are expected in the fourth quarter of 2019.
- In parallel with advancing its Phase 3 study, Minerva is continuing preparatory work for regulatory filing and commercialization. These activities include clinical pharmacology studies and manufacturing of registration batches.
- Pre-clinical data presented at the 2019 Congress of the Schizophrenia International Research Society suggest a mechanistic role for roluperidone in addressing negative symptoms. Presenters also indicated the potential of roluperidone for disease modification and improved neuroplasticity.
Seltorexant (MIN-202 or JNJ-42847922), under joint development with Janssen Pharmaceutica NV (Janssen):
- Three Phase 2b clinical trials are ongoing with seltorexant, including two in MDD and one in insomnia disorder.
- In the first MDD trial, designated as the 2001 trial (Clinicaltrials.gov Identifier: NCT03227224), patient enrollment has been completed, with 287 patients enrolled at clinical sites in the U.S., Europe and Japan. Top-line results from this trial are expected in the second quarter of 2019.
- Enrollment has also been completed in the insomnia trial, designated as the 2005 trial (Clinicaltrials.gov Identifier: NCT03375203), with approximately 360 patients enrolled at clinical sites in the U.S., Europe and Japan. Top-line results are expected in the second quarter of 2019.
- In the second MDD trial, designated as the 2002 trial (Clinicaltrials.gov Identifier NCT03321526), patient enrollment has also been completed, with 100 patients enrolled at clinical sites in the U.S. Top-line results from this trial are expected in the third quarter of 2019.
- A Phase 2b trial is ongoing with MIN-117 to treat patients diagnosed with MDD and associated anxiety disorders (Clinicaltrials.gov Identifier: NCT03446846). Approximately 324 patients are expected to be enrolled at 40 clinical sites in the U.S. and Europe. Completion of enrollment is now expected in the third quarter of 2019, with top-line results expected to be available in the fourth quarter of 2019.
First Quarter 2019 Financial Results
Net Loss: Net loss was $15.8 million for the first quarter of 2019, or a loss per share of $0.41 (basic and diluted), compared to a net loss of $12.4 million for the first quarter of 2018, or a loss per share of $0.32 (basic and diluted).
R&D Expenses: Research and development (R&D) expenses were $11.6 million in the first quarter of 2019, compared to $8.4 million in the first quarter of 2018. The increase in R&D expenses primarily reflects higher development expenses for the Phase 3 clinical trial of roluperidone and the Phase 2b clinical trial of MIN-117. R&D expenses are expected to increase during 2019 with increased patient enrollment and related support activities for the roluperidone and MIN-117 clinical trials.
G&A Expenses: General and administrative (G&A) expenses were $4.7 million in the first quarter of 2019, compared to $4.3 million in the first quarter of 2018. This increase in G&A expenses was primarily due to an increase in non-cash stock-based compensation expenses and salary costs from increased staffing to support the Company’s pre-commercial activities.
- Cash Position: Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2019 were approximately $79.3 million.
Conference Call Information:
Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities. To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 5697837.
The live webcast can be accessed under “Events and Presentations” in the Investors and Media section of Minerva’s website at ir.minervaneurosciences.com. The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the timing and scope of future clinical trials and results of clinical trials with these compounds; the clinical and therapeutic potential of these compounds; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management’s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-Q for the quarter ended March 31, 2019, filed with the Securities and Exchange Commission on March 6, 2019. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
|CONDENSED CONSOLIDATED BALANCE SHEET DATA|
|March 31,||December 31,|
|Cash and cash equivalents||$||30,608||$||50,235|
|Prepaid expenses and other current assets||1,054||1,921|
|Total current assets||80,319||90,019|
|Marketable securities - noncurrent||-||-|
|Other noncurrent assets||15||15|
|Operating lease right-of-use assets||371||-|
|In-process research and development||34,200||34,200|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accrued expenses and other current liabilities||3,721||1,810|
|Total current liabilities||6,903||3,609|
|Other noncurrent liabilities||-||29|
|Noncurrent operating leases||243||-|
|Additional paid-in capital||307,800||304,814|
|Total stockholders' equity||77,424||90,265|
|Total Liabilities and Stockholders' Equity||$||129,803||$||139,136|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
Three Months Ended March 31,
(in thousands, except per share amounts)
|Research and development||11,606||8,449|
|General and administrative||4,706||4,294|
|Total operating expenses||16,312||12,743|
|Foreign exchange losses||(6||)||(18||)|
|Loss before income taxes||(15,827||)||(12,418||)|
|Benefit for income taxes||-||-|
|Net (loss) income||$||(15,827||)||$||(12,418||)|
|Loss per share:|
|Basic and diluted||$||(0.41||)||$||(0.32||)|
|Weighted average shares:|
|Basic and diluted||38,968||38,749|
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
All Regulatory Clearances for Saxo Bank and BinckBank obtained to close the Offer23.7.2019 18:20:00 CEST | Press release
This is a joint press release by BinckBank N.V. (BinckBank), Star Bidco B.V. (the Offeror) and Saxo Bank A/S (Saxo Bank, pursuant to Section 4, paragraph 3 of the Dutch decree on public takeover bids (Besluit openbare biedingen Wft) in connection with the recommended public offer by the Offeror for all the issued and outstanding ordinary and priority shares in the capital of BinckBank (the Offer). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the Offer Memorandum dated 12 March 2019 (the Offer Memorandum). This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States or Canada or in any other jurisdiction in which such release, publication or distribution would be unlawful. Terms not defined in this press release will have the meaning as set forth in the Offer Memorandum. All Regulatory Cleara
Golar LNG Partners LP Cash Distributions23.7.2019 18:13:00 CEST | Press release
Golar LNG Partners LP (“the Partnership”) (NASDAQ: GMLP) announced today that its board of directors has approved a quarterly cash distribution with respect to the quarter ended June 30, 2019 of $0.4042 per common and general partner unit. This cash distribution will be paid on August 14, 2019 to all common and general partner unitholders of record as of the close of business on August 7, 2019. A cash distribution of $0.546875 per Series A preferred unit (NASDAQ: GMLPP) for the period from May 15, 2019 through August 14, 2019 has also been declared. This will be payable on August 15, 2019 to all Series A preferred unitholders of record as at August 8, 2019. Golar LNG Partners LP Hamilton, Bermuda July 23, 2019 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
EUROCOMMERCIAL PROPERTIES N.V. TRANSACTIONS BUYBACK PROGRAMME23.7.2019 18:05:00 CEST | Press release
Date: 23 July 2019 Release: After close of business Euronext Please open the following link to read the full report including annexes: Attachment Full press release
ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2019 RESULTS23.7.2019 18:00:00 CEST | Press release
Almere, The Netherlands July 23, 2019, 6 p.m. CET ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2019 RESULTS ASM International N.V. (Euronext Amsterdam: ASM) today reports its second quarter 2019 operating results (unaudited) in accordance with IFRS. FINANCIAL HIGHLIGHTS EUR million Q2 2018 Q1 2019 Q2 2019 New orders 175.9 235.0 373.1 Net sales 208.7 248.8 363.3 Gross profit margin % 42.1 % 41.3 % 59.0 % Operating result 38.3 47.0 150.2 Result from investments (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013) 21.6 3.1 2.0 Amortization intangible assets (resulting from the sale of ASMPT stake in 2013) (3.0 ) (3.4 ) (3.4 ) Net earnings 59.4 49.4 121.6 Normalized net earnings (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013 and result from sale of ASMPT shares) 62.4 52.8 125.0 • New orders were €373 million. Excluding €103 million related to the patent litigation settlement new orders were €270 million. • Net
Banks net position in the Riksbank23.7.2019 16:40:00 CEST | Press release
Jul 23, 2019 SEK MILLION LENDING BORROWING 271
TGS and EnergyIQ Announce Collaboration to Launch EIQ TGS Data Loader23.7.2019 15:00:00 CEST | Press release
Houston, Texas (July 23, 2018) – TGS, a leading provider of multi-client geoscience and engineering data for Exploration & Production companies, today announced the EIQ TGS Data Loader, developed in collaboration with EnergyIQ. Now, companies can automatically blend industry leading data with proprietary customer data in an enterprise well master data management platform for advanced analysis and decision making. The EIQ TGS Loader processes the most up-to-date and complete data by automatically accessing and processing TGS web services. This data is matched, validated and blended with other proprietary and third-party sources within a PPDM gold compliant data model to create the most trusted version all available data in a single repository. The data is then provided in a 10/12/14 digit format for consumption by enterprise, interpretation, and analytics applications. Carl Neuhaus, Vice President - Well Data Products of TGS, said, “We are excited to partner with EnergyIQ to make access